SCHEMBL1944223

SCHEMBL1944223

COc1ccc(Cn2nc(O[C@H]3CCCNC3)c3c(Oc4ccc(NC(=O)c5ccnn(-c6ccc(F)cc6)c5=O)cc4F)ccnc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AXL P30530 19/20 0.55
MERTK Q12866 19/20 0.55
TYRO3 Q06418 15/20 0.55
MET P08581 19/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1944226 1.00 AXL (0.55) AXLMERTKTYRO3MET
SCHEMBL3273395 0.95 AXL (0.50) AXLMERTKTYRO3MET
SCHEMBL1943791 0.94 MET (0.55) AXLMERTKTYRO3MET
SCHEMBL1944677 0.90 AXL (0.53) AXLMERTKTYRO3MET
SCHEMBL1944230 0.90 AXL (0.53) AXLMERTKTYRO3MET
SCHEMBL1944232 0.90 AXL (0.53) AXLMERTKTYRO3MET
SCHEMBL1947699 0.89 AXL (0.52) AXLMERTKTYRO3MET
SCHEMBL1944431 0.89 MET (0.58) AXLMERTKTYRO3MET
SCHEMBL1945962 0.88 AXL (0.51) AXLMERTKTYRO3MET
SCHEMBL1944485 0.88 AXL (0.51) AXLMERTKTYRO3MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130406-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-02 US disclosed
EP-2193130-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-06-09 EP disclosed
WO-2009033084-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130406-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS TYRO3, LCK, LTK AXL 43/4885MERTK 63/4885TYRO3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.